Table 3 Characteristics of patients with FCHL included in the longitudinal study before and after treatment for their dyslipidemia
From: Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment
Off- treatment | With treatment | P | |
|---|---|---|---|
25(OH)D (nmol/L) | 51.0 ± 31.3 | 58.9 ± 24.6 | 0.022 |
BMI (Kg/m2) | 26.6 ± 2.6 | 26.6 ±2.6 | 0.778 |
Waist (cm) | 92.7 ± 9.2 | 93.1 ± 8.8 | 0.518 |
HOMA | 2.0 ± 1.1 | 2.2 ± 1.4 | 0.535 |
Total cholesterol (mmol/L) | 7.4 (5.1-16.1) | 5.1 (3.8-8.9) | 0.000 |
Triglycerides (mmol/L) | 2.8 (1.2-10.7) | 1.9 (0.8-3.8) | 0.000 |
LDL-c (mmol/L) | 4.3 (1.4-7.8) | 3.0 (2.0-5.8) | 0.007 |
HDL-c (mmol/L) | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.000 |
VLDL-c (mmol/L) | 1.3 (0.6-8.6) | 0.9 (0.4-3.3) | 0.000 |
NEFA (mmol/L) | 0.6 (0.3-1.6) | 0.6 (0.3-1.4) | 0.313 |
ApoB (g/L) | 1.4 ± 0.3 | 1.0 ± 0.2 | 0.000 |
LDLsize (nm) | 25.3 (23.2-26.2) | 25.7 (24.8-26.5) | 0.058 |
CRP (mg/L) | 2.0 (0.1-21.1) | 1.3 (0.3-12.2) | 0.823 |